REV. FEBRUARY 2019

The University of Rhode Island (URI) Institutional Biosafety Committee (IBC) serves as the IBC for the URI. The mission of the IBC is to promote safety and minimize the risks of performing Biological Research to URI investigators, study participants, the community, and the environment by providing scientific review and oversight to Biological Research at URI. The IBC is committed to following the letter and the spirit of biosafety guidelines, guidance, and regulations. The IBC shall operate in full compliance with all applicable federal, state, and local regulations.

Instructions

Research requiring Registration

Use this form to register research with:

- Potentially infectious agents (regardless of pathogenicity to humans) (e.g., bacteria, viruses, fungi, parasites, prions, rickettsias, yeasts, etc.)
- Recombinant DNA molecules, exempt or non-exempt from NIH Guidelines (e.g., recombinant or attenuated viral vectors, use of rDNA to create transgenic plants or animals)
- Human and nonhuman primate materials, including blood, tissues, and cell lines (primary and established)
- Biological toxins subject to the Select Agent Regulations

Form Submittal

Submit via IRBNet the following:

- This Registration Document
- Any attachments
- Relevant thesis, dissertation, or grant proposals

Adobe Forms

- Check that you have installed the latest version of Adobe Acrobat or Reader. The link to install Adobe Reader is: http://get.adobe.com/reader
- Download the IBC Registration Document
- Mac and iOS Users, open the file using Adobe Reader rather than the Preview function built into your Mac OS.
- Windows users, open the file using Adobe Acrobat or Reader rather than using a web browser.
- Save the form once you have entered your information. Then submit the form for IBC review via IRBNet

Timetable

Refer to the IBC meeting schedule on the URI Research Integrity website for submission deadlines

IBC Review and Approval Cycle

All IBC approvals require a renewal at their five year expiration. For renewals, submit an updated **Registration Document for Biological Research (New and Five Year Renewal).**

Questions?

- Contact the Office of Research Integrity at 401-874-4328
- For training materials on IRBNet, refer to the Office of Research Integrity website
- For information on biosafety training, contact <u>URI EH&S Office</u> at 874-7993.

OFFICE OF RESEARCH INTEGRITY

BIOSAFETY REGISTRATION DOCUMENT FOR BIOLOGICAL RESEARCH (NEW AND FIVE YEAR RENEWAL)

REV. FEBRUARY 2019

IBC Registration Document Completion Checklist

The checklist provided is an optional tool for researchers that clearly defines the requirements for IBC registration document submission. Use this to make sure all of the required documents are being uploaded to IRBNet and all personnel associated with your project receive the necessary training.

Completed Registration Document for Biological Research. Please try to limit your answers to the space provided and focus on the biological research . (Upload separate document if you believe additional information is valuable to the committee. Refer to specific questions you are addressing).
Attach an inventory sheet of all biological research materials you will be using for this protocol. Provide the location where each material will be stored.
Attach information detailing how you will obtain the biological materials for this protocol (e.g., commerical vendor)
Attach copies of your laboratory's Standard Operating Procedures (SOPs).
All personal are required to attend an in-person biosafety training class with Connie Heird, Chemical Hygiene/Biosafety Officer, Environmental Health & Safety Office. After the initial training, annual training is required and can be completed by attending further trainings with Connie Heird, or taking the CITI training modules (www. citiprogram.org) relevant to your research. The following modules are offered:
Basic Biosafety Training Animal Biosafety Training Shipping and Transport of Regulated Biological Materials OSHA Bloodborne Pathogens
Attach relevant thesis, dissertation, or grant proposals.
Attach signed Proposal Approval form, if part of a thesis/dissertation.
In-person biosafety training classes are offered all year round. Participants must visit the Environmental

Health & Safety <u>Training Schedules and Handouts</u> page for training dates and registration information.

Questions?

- Contact the Office of Research Integrity at 401-874-4328
- For training materials on IRBNet, refer to the Office of Research Integrity website
- For information on biosafety training, contact <u>URI EH&S Office</u> at 874-7019.

REV. FEBRUARY 2019

Section 1 - Administr	ative Information Preview	DER FOR MAC USERS: Complete form in Adobe Reader, not the variation in MAC OS. Using the Preview function will disable fithe form.				
a. Principal Investigator						
b. College / Department						
c. Email		d. Phone Number				
e. Project Title						
f. Type of application	New Registration List Properties (BI #)	rotocol				
g. Anticipated Research S	tart Date	Anticipated Research End Date				
h. What sponsored research projects support this research? List the title(s), sponsor, URI Project ID # , current period of performance.						
i. Where will the research (Include Building/Roon	•					
j. Date of Biosafety Trainir	ng					
Collaboration						
k. Does this project involve collaboration with another institution? No Yes No If yes, please be clear in Section 3 what portions of the work will not be conducted at URI.						
This Registration Document for Biological Research is for work involving: (More than one category may apply)						
Potentially infectous	s agents	Complete Sections 2, 3, 4, 5, and 9				
Recombinant DNA r vectors) or synthetic	molecules (e.g., plasmids, viral c nucleic acids	Complete Sections 2, 3, 4, 6, and 9				
Human or nonhumatissue, cell lines)	an primate materials (e.g., blood,	Complete Sections 2, 3, 4, 7, and 9				
Biological toxins sub	pject to the Select Agent Regulatio	ns Complete Sections 2, 3, 4, 8 and 9				

Associated Approvals:

Committee	Description	Approval Number or Review Status (e.g., pending, under review)
IACUC	Conducting Biological Research with animals (e.g., introducing infectious agent, viral vector) require IACUC approval	
IIKK	Collecting biological specimens from human subjects (e.g., blood draws) require IRB approval	

REV. FEBRUARY 2019

Section 2 - Personnel

List all personnel associated with the project				
a. Co-investigator				
Name	Department			
Email	Phone Number			
Date of Biosafety Training				
b. Student Researcher				
Name	Department			
Email	Phone Number			
Date of Biosafety Training				
Will this project be used as a thesis or dissertation research, independent study or research paper?	on proposal, directed Yes	f yes, submit an electronic copy of hat proposal/paper as part of the RBnet package		
c. Other Personnel All personnel should complete biosafety training o	offered by URI FHS			
Name	Position	Date of Biosafety Training		
Describe any relevant experience				

REV. FEBRUARY 2019

Section 3 - Description of Research

a. Please provide a brief description of the goals of the Biological Research. Write for non-specialists.
b. Provide a detailed description of specific experiments you will be conducting, focusing how the infectious agent, rDNA materials, human or nonhuman primate materials, or toxin will be used. If conducting more than one experiment, list them as A, B, C, etc. in order for the committee to easily distinguish between the procedures.

REV. FEBRUARY 2019

Use t	he space provided be	low to continue you	r answer to questior	b if necessary.	

Office of Research Integrity

BIOSAFETY REGISTRATION DOCUMENT FOR BIOLOGICAL RESEARCH (NEW AND FIVE YEAR RENEWAL)

REV. FEBRUARY 2019

Section 4 - Risk Assessment

NIH requires Principal Investigators make an initial determination of the required levels of physical and biological containment in accordance with the NIH Guidelines

b. Work will be perform	ned at:				
☐ Biosafety Level 1	☐ Animal B	iosafety Level 1	1 Comments		
☐ Biosafety Level 2	☐ Animal B	iosafety Level 2			
c. Will a biosafety cabir containment?	net be used for	○Yes List	t date of last BSC tification:		BSCs must be certified annually
If yes, which procedures specifically?					
d. Describe personal prequipment being us research (e.g., glove protection, lab coat)	sed for this es, eye				
e. Are any vaccinations conduct this researc hepatitis B vaccine)	ch (e.g.,				

OFFICE OF RESEARCH INTEGRITY

BIOSAFETY REGISTRATION DOCUMENT FOR BIOLOGICAL RESEARCH (NEW AND FIVE YEAR RENEWAL)

REV. FEBRUARY 2019

Section 5 - Research with Potentially Infectious Agents

Complete this section if you are working with potentially infectious agents (regardless of the pathogenicity to humans or animals). Provide the information requested below for each agent.

a. Name of agent(s):			
b. Source of agent(s)			
c. Is antibiotic resistance expressed?	○Yes ○No	If yes, describe:	
d. Is toxin produced?	○ Yes ○ No	If yes, describe:	
e. Largest volume of agent cultured?			
f. Is agent concentrated?	○ Yes ○ No	If yes, what is the highest concentration?	
g. Describe how agent(s) will be inactivated (e.g., bleach, autoclave). Describe specific parameters (e.g., disinfectant concentration)			
h. Will the agent be introduced into animal	Yes s? No		Don't forget to upload your spill protocol and other relevant SOPs.
i. If yes to h, describe administration o special housing requirements.	of agent to a	nimal including route	of administration (e.g., IM, IP, IV), dose, and any

OFFICE OF RESEARCH INTEGRITY

BIOSAFETY REGISTRATION DOCUMENT FOR BIOLOGICAL RESEARCH (NEW AND FIVE YEAR RENEWAL)

REV. FEBRUARY 2019

Section 6 - rDNA / Synthetic Nucleic Acids Research

NIH Guideline Section

NIH requires that Principal Investigators indicate the Section of the NIH Guidelines that covers their research. For specific language from the NIH, refer to the NIH Guidelines.

NIH Guideline Section	Example(s)		
Section III-A	Transfer of a drug resistant gene into a microorganisms that do not acquire the gene naturally that could compromise the use of the drug to control disease in humans, veterinary medicine or agriculture.		
Section III-B	Cloning of genes for toxins with LD50 of > 10 ng/kg body weight.		
Section III-C	Deliberate transfer of recombinant DNA, or DNA or RNA derived from recombinant DNA, into human research participants (human gene transfer)		
Section III-D	Introduction of rDNA or synthetic nucleic acid molecules into risk group 2 agents. rDNA from Risk Group 2, 3, 4 or restricted agents or use as host vector systems. Some experiments involving whole animals or plants. Large scale experiments. (e.g, use of adenoviral vectors, lentiviral vectors, retroviral vectors)		
Experiments involving formation of rDNA or synthetic nucleic acid molecules containing no 2/3 of the genome of any eukaryotic virus. Some experiments with whole plants. Creation of transgenic rodents that require BSL1 containment.			
Section III-F	Experiments involving rDNA that are not in organisms or viruses.		
	vector(s), DNA and proteins that will be produced. Typically this work falls under Section III-E or III-F of the NIH hat Section C describes their use		
c. What genes will be inse	erted DNA?		
d. What are the gene pro- (e.g., physiological activit potential)			
e. Protein produced (if ap	pplicable)		
f. Other Information (e.g., rDNA to animals)	introducing		

OFFICE OF RESEARCH INTEGRITY

BIOSAFETY REGISTRATION DOCUMENT FOR BIOLOGICAL RESEARCH (NEW AND FIVE YEAR RENEWAL)

REV. FEBRUARY 2019

Section 6 - rDNA / Synthetic Nucleic Acids Research

Complete this section if you are generating and/or using viral vectors in your laboratory. Typically this work falls under Section III-D of the NIH Guidelines g. Identify Vector System Adeno-associated virus ☐ Adenovirus Other (e.g., vaccinia, HSV) Retrovirus Lentivirus Provide full name(s) of vectors (include all associated plasmids) h. List host cell line or packaging cells for vector propagation: i. Source of vector system (e.g., vendor) j. Is the vector capable of infecting human cells? (e.g., VSVg pseudotyped lentivirus) \(\cap \text{No} \) k Describe the function and activity of the transgene(s). If you are planning on using an extensive number of transgenes, list classes or submit a separate file. If you are using a genome wide approach, describe library. I. Are the expressed transgenes known or If yes, please suspected to be oncogenic, potentially describe: oncogenic, a tumor suppressor, or, to \bigcirc No alter the cell cycle? m. Source of gene(s) (genus/species) n. Describe how agent will be inactivated (e.g., bleach, autoclave). Describe specific parameters (e.g., disinfectant concentration) Yes o. Will the agent be introduced into If yes, describe animals? administration of \bigcirc No agent including route of administration (e.g., Use of live animals also requires IACUC approval. IM, IP, IV), dose, and any special housing requirements.

REV. FEBRUARY 2019

Section 7 - Research with Human or Nonhuman Primate Materials

Complete this section if you are working with human or nonhuman primate materials (e.g., blood, tissue, cell lines, other potentially infectious materials as defined by OSHA)

micetious materials as defined by <u>ossim</u>				
a. Identify the type (e.g., blood, cell line, tissue) and source (e.g., vendor, colleague) of the materials to be used. For cell lines, indicate if the cells are established or primary.				
b. List any information that may be relevant to the infectious risk of the materials to be used (e.g., known to be infected with specific agent, known to be tested for presence of bloodborne pathogens)				
c. Will sharps be used with the materials?	⊜Yes ⊝No	If yes, describe:		
d. Describe how agent will be inactivated (e.g., bleach, autoclave). Describe specific parameters (e.g., disinfectant concentration)				
e. Will the human or nonhuman primate material be introduced into animals?	○Yes ○No			Don't forget to upload your spill protocol and other relevant SOPs.
f. If yes to e, describe administration o special housing requirements.	f material to	o animal incl	uding rout	e of administration (e.g., IM, IP, IV), dose, and any

REV. FEBRUARY 2019

Section 8 - Research with Biological Toxins

Complete this section if you are working with a toxin of biological origin, subject to the <u>Select Agent Regulations</u>.

a. Identify the toxin, source (e.g., vendor, colleague), and largest quantity of toxin in use and stored.	
b. Describe how the toxin will be stored.	
c. Describe the toxin deactivation/disposal procedures.	

OFFICE OF RESEARCH INTEGRITY

BIOSAFETY REGISTRATION DOCUMENT FOR BIOLOGICAL RESEARCH (NEW AND FIVE YEAR RENEWAL)

REV. FEBRUARY 2019

Section 9 - Certifications and Endorsements by Principal Investigator

To indicate agreement, check each statement and sign below

To the best of my knowledge the information provided in this protocol form is complete and accurate and that this application accurately and completely reflects the Biological Research described in my full grant applications (if applicable).
I am familiar with and agree to abide by the University's policies for research with potentially biohazardous materials, as based on the provisions of the NIH Guidelines and the Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition.
I understand that failure to comply with the NIH Guidelines, may jeopardize my research grants and those of others at the University regardless of the funding sources for my research.
I am trained in good microbiological techniques and will ensure that all laboratory staff involved with this research are adequately trained and have completed University sponsored biosafety training and laboratory and project specific training and any additional training, instruction, and supervision needed to work safely with the biological agents and materials involved.
I understand that I am responsible to report immediately to the IBC any significant violations of the NIH Guidelines, problems with containment, and any significant research-related accidents or illnesses.
I agree to notify the IBC of changes in the research described in the application and will submit a revised IBC Registration to the IBC for review.
Principal Investigator Sign-Off
Please print name

Print the form for your records